Partnerships

Synageva is focused on efficiently developing and commercializing its pipeline of novel for rare diseases to provide patients access to important therapies for their conditions.

We  intend to further our mission to reach these patients by establishing partnerships with organizations  for our development programs that target large specialty markets (as these are not part of Synageva’s core focus), and for leveraging our proprietary technology:

• Co-development and/or out-licensing agreements for Synageva's proprietary product programs. These include two bio-better monoclonal antibodies with enhanced ADCC activity, a bio-similar cytokine that has successfully completed a global Phase 2 clinical trial, and a potentially bio-better long-acting cytokine.
• Expression, scale-up, and manufacturing of a partner's biopharmaceutical programs utilizing the SEP™ Protein Technology
• Co-development and/or in-licensing agreements for novel treatments for rare diseases

Please direct any partnership inquires to: